Skip to main content
. 2017 Aug 10;22(11):1333–1338. doi: 10.1634/theoncologist.2017-0088

Figure 3.

image

Survival for human epidermal growth receptor 2 positive patients in real world. (A): DFS in early stage breast cancer. (B): PFS of first line in metastatic breast cancer. (C): PFS of patients who never received trastuzumab in early stage. (D): PFS of patients who had received trastuzumab in early stage.

Abbreviations: CI, confidence interval; DFS, disease‐free survival; HR, hazard ratio; m, months; N, no; PFS, progression‐free survival; T, trastuzumab; Y, yes.